One Dose Risankizumab Effectiveness in Psoriasis: A Real-Life Multicentre Study

IF 3.7 4区 医学 Q1 DERMATOLOGY Dermatologic Therapy Pub Date : 2024-06-13 DOI:10.1155/2024/4866592
Jorge Magdaleno-Tapial, José María Ortiz-Salvador, Sergio Santos-Alarcón, Isabel Belinchón-Romero, Antonio Sahuquillo-Torralba, Víctor González-Delgado, Javier Sabater-Abad, Miquel Armengot-Carbó, Juan Ignacio Marí-Ruíz, Almudena Mateu-Puchades, Javier Mataix-Díaz, Luca Schneller-Pavelescu, Rafael Carmena-Ramón, Antonio Martorell, José Luis Sánchez-Carazo
{"title":"One Dose Risankizumab Effectiveness in Psoriasis: A Real-Life Multicentre Study","authors":"Jorge Magdaleno-Tapial,&nbsp;José María Ortiz-Salvador,&nbsp;Sergio Santos-Alarcón,&nbsp;Isabel Belinchón-Romero,&nbsp;Antonio Sahuquillo-Torralba,&nbsp;Víctor González-Delgado,&nbsp;Javier Sabater-Abad,&nbsp;Miquel Armengot-Carbó,&nbsp;Juan Ignacio Marí-Ruíz,&nbsp;Almudena Mateu-Puchades,&nbsp;Javier Mataix-Díaz,&nbsp;Luca Schneller-Pavelescu,&nbsp;Rafael Carmena-Ramón,&nbsp;Antonio Martorell,&nbsp;José Luis Sánchez-Carazo","doi":"10.1155/2024/4866592","DOIUrl":null,"url":null,"abstract":"<div>\n <p><i>Background</i>. Rapid efficacy is an important item to psoriasis patients. Risankizumab, a humanised immunoglobulin G1 monoclonal antibody that inhibits IL-23, has demonstrated early and sustained efficacy in patients with moderated-to-severe psoriasis. Effectiveness data in real world, particularly regarding short-term response, however, are scarce. <i>Objective</i>. To explore the short-term effectiveness of risankizumab in patients with moderate-severe psoriasis in normal clinical practice. <i>Methods</i>. This was an observational, retrospective, multicentre study carried out at thirteen hospitals in Valencia, Spain. It was conducted on a sample of adult outpatients over 18 years of age, diagnosed with moderate-to-severe psoriasis who received at least one subcutaneous injection of 150 mg of risankizumab. Psoriasis Area and Severity Index (PASI) was used to assess the short-term (4 weeks) effectiveness of risankizumab. <i>Results</i>. One hundred and sixteen patients (63.8% men) with a mean age (standard deviation (SD)) of 50 (16) years were included in the study. 90.6% were overweight or obese, and 22.7% were biologic-naïve. The mean (SD) PASI score decreased from 11.9 (7.2) at the baseline to 3.3 (2.7) at week 4, with a median (SD) PASI score reduction of 8.6 (2.3) (<i>p</i> &lt; 0.05). The absolute PASI score of &lt;2 was reached by 52.6% of patients. Overall, PASI scores of 75, 90, and 100 were achieved in 56%, 37.1%, and 25.9% of patients, respectively, at week 4. PASI 90 was achieved by a significantly higher proportion of naïve patients than biologic-experience failure patients (59.3% vs. 30.3%; <i>p</i> = 0.01). <i>Conclusion</i>. This study, which reflects our initial risankizumab experience in a real-life setting, seems to show quick effectiveness in psoriasis treatment after one single dose. This trial is registered with NCT04862286.</p>\n </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2024 1","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2024-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/4866592","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatologic Therapy","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/2024/4866592","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background. Rapid efficacy is an important item to psoriasis patients. Risankizumab, a humanised immunoglobulin G1 monoclonal antibody that inhibits IL-23, has demonstrated early and sustained efficacy in patients with moderated-to-severe psoriasis. Effectiveness data in real world, particularly regarding short-term response, however, are scarce. Objective. To explore the short-term effectiveness of risankizumab in patients with moderate-severe psoriasis in normal clinical practice. Methods. This was an observational, retrospective, multicentre study carried out at thirteen hospitals in Valencia, Spain. It was conducted on a sample of adult outpatients over 18 years of age, diagnosed with moderate-to-severe psoriasis who received at least one subcutaneous injection of 150 mg of risankizumab. Psoriasis Area and Severity Index (PASI) was used to assess the short-term (4 weeks) effectiveness of risankizumab. Results. One hundred and sixteen patients (63.8% men) with a mean age (standard deviation (SD)) of 50 (16) years were included in the study. 90.6% were overweight or obese, and 22.7% were biologic-naïve. The mean (SD) PASI score decreased from 11.9 (7.2) at the baseline to 3.3 (2.7) at week 4, with a median (SD) PASI score reduction of 8.6 (2.3) (p < 0.05). The absolute PASI score of <2 was reached by 52.6% of patients. Overall, PASI scores of 75, 90, and 100 were achieved in 56%, 37.1%, and 25.9% of patients, respectively, at week 4. PASI 90 was achieved by a significantly higher proportion of naïve patients than biologic-experience failure patients (59.3% vs. 30.3%; p = 0.01). Conclusion. This study, which reflects our initial risankizumab experience in a real-life setting, seems to show quick effectiveness in psoriasis treatment after one single dose. This trial is registered with NCT04862286.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
单剂量利桑珠单抗对银屑病的疗效:一项真实多中心研究
背景。对银屑病患者来说,快速疗效是一个重要的项目。利桑珠单抗是一种抑制 IL-23 的人源化免疫球蛋白 G1 单克隆抗体,对中度至重度银屑病患者具有早期和持续的疗效。然而,现实世界中的疗效数据,尤其是有关短期反应的数据却很少。研究目的探讨利桑珠单抗在正常临床实践中对中度至重度银屑病患者的短期疗效。方法。这是一项观察性、回顾性、多中心研究,在西班牙巴伦西亚的 13 家医院进行。研究对象为 18 岁以上、被诊断为中度至重度银屑病、至少接受过一次 150 毫克利桑珠单抗皮下注射的成年门诊患者。银屑病面积和严重程度指数(PASI)用于评估利坦珠单抗的短期(4 周)疗效。研究结果116名患者(63.8%为男性)参加了研究,平均年龄(标准差(SD))为50(16)岁。90.6%的患者超重或肥胖,22.7%的患者对生物制剂一无所知。平均(标清)PASI评分从基线时的11.9(7.2)分降至第4周时的3.3(2.7)分,中位(标清)PASI评分降低了8.6(2.3)分(p < 0.05)。52.6%的患者 PASI 绝对值达到 2 分。总体而言,第 4 周时分别有 56%、37.1% 和 25.9% 的患者 PASI 达到 75、90 和 100 分。达到 PASI 90 分的新患者比例明显高于有生物制剂治疗经验的失败患者(59.3% 对 30.3%;P = 0.01)。结论这项研究反映了我们在现实生活中使用利桑珠单抗的初步经验,似乎显示出单次用药后对银屑病治疗的快速疗效。该试验已在 NCT04862286 上注册。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Dermatologic Therapy
Dermatologic Therapy 医学-皮肤病学
CiteScore
7.00
自引率
8.30%
发文量
711
审稿时长
3 months
期刊介绍: Dermatologic Therapy has been created to fill an important void in the dermatologic literature: the lack of a readily available source of up-to-date information on the treatment of specific cutaneous diseases and the practical application of specific treatment modalities. Each issue of the journal consists of a series of scholarly review articles written by leaders in dermatology in which they describe, in very specific terms, how they treat particular cutaneous diseases and how they use specific therapeutic agents. The information contained in each issue is so practical and detailed that the reader should be able to directly apply various treatment approaches to daily clinical situations. Because of the specific and practical nature of this publication, Dermatologic Therapy not only serves as a readily available resource for the day-to-day treatment of patients, but also as an evolving therapeutic textbook for the treatment of dermatologic diseases.
期刊最新文献
Clinical Experience With Brentuximab Vedotin in Treating Cutaneous T-Cell Lymphoma: A Retrospective Review From China Pharmaceutical Management of Rosacea—An Australian/New Zealand Medical Dermatology Consensus Narrative A3669G Polymorphism of Glucocorticoid Receptor Is More Present in Patients With Pemphigus Vulgaris Than in Healthy Controls and Contributes to Steroid-Resistance Baricitinib for the Treatment of Chronic Pruritus of Unknown Origin Patient Awareness, Education, and Support for Atopic Dermatitis in Egypt and Lebanon: Results of a Physician Survey and Social Analytics
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1